NASDAQ:CTMX - CytomX Therapeutics Stock Price, News & Analysis

$9.34
+0.27 (+2.98 %)
(As of 08/18/2019 11:28 AM ET)
Today's Range
$9.08
Now: $9.34
$9.80
50-Day Range
$8.91
MA: $10.84
$12.41
52-Week Range
$8.78
Now: $9.34
$24.34
Volume467,500 shs
Average Volume315,669 shs
Market Capitalization$424.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.63
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.50 million
Book Value$2.24 per share

Profitability

Net Income$-84,600,000.00
Net Margins-158.05%

Miscellaneous

Employees137
Market Cap$424.13 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.


CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) announced its earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.64) EPS for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.09. The biotechnology company earned $9.01 million during the quarter, compared to analysts' expectations of $15.11 million. CytomX Therapeutics had a negative return on equity of 77.05% and a negative net margin of 158.05%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

10 brokerages have issued 12 month price objectives for CytomX Therapeutics' stock. Their predictions range from $13.24 to $34.00. On average, they expect CytomX Therapeutics' share price to reach $20.9156 in the next year. This suggests a possible upside of 123.9% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.

What is the consensus analysts' recommendation for CytomX Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (8/15/2019)
  • 2. Nomura analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019)
  • 4. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019)

Has CytomX Therapeutics been receiving favorable news coverage?

Media headlines about CTMX stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CytomX Therapeutics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for CytomX Therapeutics.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
  • Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
  • Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
  • Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
  • Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.57%), Perceptive Advisors LLC (6.95%), Price T Rowe Associates Inc. MD (6.17%), Vanguard Group Inc. (5.88%), Victory Capital Management Inc. (4.37%) and Renaissance Technologies LLC (3.11%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Lloyd A Rowland, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Price T Rowe Associates Inc. MD, Allianz Asset Management GmbH, Wells Fargo & Company MN, D. E. Shaw & Co. Inc., Congress Park Capital LLC, Charles Schwab Investment Management Inc. and Bank of America Corp DE. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Victory Capital Management Inc., Vanguard Group Inc., Morgan Stanley, Prudential Financial Inc., Renaissance Technologies LLC, A.R.T. Advisors LLC and Algert Global LLC. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $9.34.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $424.13 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.View Additional Information About CytomX Therapeutics.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is http://www.cytomx.com/.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel